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Abstract
Background: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland
malignancies treated with surgery followed by adjuvant chemoradiotherapy.
Methods: From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed
by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal
involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles:
the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m
2 on d1), infusional 5-fluorouracil (600
mg/m
2/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without
treatment.
Results: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n
= 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment
related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required
feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none
progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival
was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal
stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1).
Conclusions: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control
for high-risk salivary malignancy patients.
Background
Salivary gland cancers comprise 3-6% of all head and
neck malignancies [1,2]. Although they are commonly
grouped together, these cancers are histologically diverse
with varying natural histories. Surgery is the established
initial treatment for salivary gland malignancies. Adju-
vant radiotherapy in patients with high-grade tumors or
high- risk features, improves locoregional control in
select patients undergoing surgical resection compared
to surgical resection alone [1,3-9]. Chemotherapy is not
routinely used outside of the palliative or recurrent
disease setting for salivary gland tumors. The most com-
monly used regimen is cyclophosphamide, doxorubicin,
and cisplatin (CAP) with response rates of 27-83%, and
few of long duration [10-13]. In small, single-institution
series, survival rates of 60-72% at 5 years have been
reported in patients receiving chemoradiotherapy for
salivary malignancies [14-18]. Previous studies from our
institution have demonstrated the combination of 5-FU,
hydroxyurea, and radiotherapy (FHX) an effective regi-
men for head and neck cancer (particularly those of
squamous histology)[19]. Based on these favorable
results we sought to improve locoregional control in
patients with advanced and high- risk salivary gland
malignancies, utilizing FHX based regimens. The present
study was undertaken to report the outcomes of patients
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diotherapy for salivary glands carcinomas.
Methods
Patient population
Between 09/1991 and 06/2007, 72 consecutive patients
with primary or recurrent salivary gland carcinoma under-
went evaluation and treatment with radiation therapy with
or without surgery or chemotherapy at University of Chi-
cago Hospitals or at a participating hospital on a Univer-
sity of Chicago protocol. From this cohort, 14 patients
with distant metastases, 10 patients with prior radiother-
apy or recurrent disease, and 15 patients receiving only
radiotherapy as adjuvant treatment were excluded from
this analysis. An additional 9 patients treated without sur-
gery were excluded. The 24 remaining patients who
received surgery followed by adjuvant chemoradiotherapy
formed our study population. All patients were evaluated
before therapeutic intervention by a medical oncologist,
radiation oncologist, and head and neck surgeon. Initial
staging procedures consisted of a history and physical,
complete head and neck exam, biopsy and/or tumor resec-
tion if feasible, tumor mapping, dental evaluation, head,
neck and chest computed tomography (CT) scan, as well
as quality of life, and speech and swallowing assessment in
most patients. All patients signed informed consent before
beginning therapy. The Institutional Review Board at the
University of Chicago approved this study.
Treatment
All patients underwent macroscopically complete onco-
logic surgical resection. The type and extent of surgery
was dependent on the primary site, surgeon’s clinical
judgment, and the patient’s willingness to undergo
resection. In general, surgical resection of all known dis-
ease at the primary and neck was recommended for all
patients. The primary goal of surgical resection was to
preserve cosmetic and functional outcome without sacri-
ficing locoregional control. Neck dissection was per-
formed most often with therapeutic intent, but also less
commonly for diagnostic purposes.
Adjuvant chemoradiotherapy was recommended for
high-risk pathologic features such as perineural involve-
ment, nodal involvement, or involved surgical margins.
Patients received 4-6 alternating week cycles of FHX-
based chemoradiotherapy based on pathologic risk factors
and radiation fractionation. Each 14-day cycle consisted of
five days of concurrent chemoradiotherapy followed by
nine days without chemotherapy or radiotherapy. Some
patients were treated on protocols investigating the inte-
gration of new agents with FHX. These included irinote-
can (5-15 mg/m
2/d × 5d), combined with concurrent
infusional 5-fluorouracil (600 mg/m
2/d × 5d), and hydro-
xyurea (500 mg PO BID); gemcitabine (50-300 mg/m
2 on
d1), combined with concurrent paclitaxel (100 mg/m
2 on
d1) and infusional 5-fluorouracil (600 mg/m
2/d × 5d), as
well as bevacizumab (2.5-10 mg/kg/m
2 on d1) combined
with infusional 5-fluorouracil (600-800 mg/m
2/d × 5d)
and hydroxyurea (500-1000 mg PO BID) (BFHX). Patients
treated off protocol were commonly treated with 5 days of
concurrent paclitaxel (100 mg/m
2 on d1), infusional 5-
fluorouracil (600 mg/m
2/d × 5d), and hydroxyurea (500
mg PO BID) (TFHX).
All patients treated after 1997 underwent CT based
treatment planning. All were immobilized in custom
masks. Treatment volumes were individualized based on
extent of surgical resection, high-risk pathological fea-
tures and extent of tumor invasion. Initially 3D confor-
mal radiotherapy was used, and as it became increasingly
available, intensity-modulated radiotherapy was used. All
patients were treated on 6 MV linear accelerators. Most
patients were treated with 1.5 Gy twice daily with a mini-
mum six-hour interfraction interval. Tumor in close
proximity to critical neural structures received a single
daily fraction of 2 Gy. Radiotherapy dose was individua-
lized based on adverse pathologic features. In general, 60
Gy was prescribed for perineural invasion or > 1 lymph
node with metastatic spread, or T3/T4 tumor status.
Patients with positive margins and extra nodal extension
were prescribed 66 Gy, and those with gross residual dis-
ease were prescribed 70-75 Gy.
All patients were evaluated weekly during chemora-
diotherapy for adverse events. Acute toxicity was graded
based on the CTCAE v 3.0. Following completion of
chemoradiotherapy patients underwent contrast
enhanced CT neck and chest one month following the
completion of therapy, then every three months for 2
years then every 6 months until five years following
completion of treatment. Late toxicity was graded using
the RTOG late toxicity scoring system.
Statistical analysis
Three- and 5-year estimates of the probability of locore-
gional control, distant-metastases free survival, disease-
free survival, and overall survival were calculated using
the Kaplan-Meier method [20]. Clinical and disease vari-
ables considered as potential predictors of outcome on
univariate analysis were: primary site, histology, T-stage,
lymph node metastasis, radiation dose, radiation fractio-
nation, and chemotherapy regimen. Events were mea-
sured from the date of initial surgery, with patient
follow-up reported to the date last seen in clinic or
identified through the Social Security Death Index.
Results
Patient Characteristics
Baseline characteristics of the population are listed in
Table 1. The median age was 62 years (range, 26-79
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gland was more frequently involved (n = 17) than minor
(n = 4) or submandibular (n = 3) gland. Tumor histol-
ogy was as follows: 5 adenoid cystic (21%), 5 mucoepi-
dermoid (21%), 3 adenocarcinoma (13%), 3 squamous
cell carcinoma (13%), 3 poorly differentiated (13%) and
6 other (25%). All primary tumors were retrospectively
staged in accordance with the 2002 American Joint
Committee on Cancer (AJCC) staging system. The three
patients with squamous cell carcinoma had no history
of skin cancers and full dermatologic examination
demonstrated no evidence of cutaneous lesions. There
was agreement that the tumors arose from salivary
gland tissue and did not represent metastatic disease
from another primary tumor.
A ss h o w ni nT a b l e1 ,t h ed i s t r i b u t i o no fc l i n i c a lo r
p a t h o l o g i cT - s t a g ew a s :1T 1 ,8T 2 ,6T 3 ,7T 4 A ,a n d2
T4B. The distribution of clinical or pathologic N-stage
w a s :6N 0 ,3N 1 ,0N 2 A ,1 4N 2 b ,1N 2 c ,a n d0N 3 .
Overall stage breakdown was as follows: 1 stage II, 2
stage III, 19 stage IVA, and 2 stage IVB. Three patients
received induction therapy before concurrent chemora-
diotherapy. Fifteen patients (63%) presented with palp-
able or radiographic evidence of N2b-N3 cervical
lymphadenopathy and 21 underwent neck dissection at
some point during treatment. The median radiation
dose was 65 Gy (R 55 Gy - 68 Gy). Median patient fol-
l o w - u pw a s4 2m o n t h s( r a n g e ,7 - 1 2 1m o n t h s )f o ra l l
patients and 43 months for survivors (range 7-95
months).
Patterns of Recurrence
Locoregional recurrence was uncommon. No patient
recurred regionally. One patient recurred locally at 14
months. This patient with a T4aN2b high-grade mucoe-
pidermoid carcinoma of the base of tongue underwent
surgical salvage and lived another 9 years before dying
of a primary lung cancer. Locoregional progression free
survival at 3 and 5 years was 96% (95% CI: 73, 99) as
shown in Figure 1. Eight patients progressed distantly.
T h el u n gw a st h em o s tc o m m o ns i t ei n v o l v e d( 6
patients), followed by brain (2 patients) and liver (2
patients). The mean time to distant progression was 23
months (range, 4 - 75 months). Two patients received
palliative chemotherapy and 1 patient received whole
brain radiotherapy for brain metastases. The mean time
to death following distant progression was 19 months
(range 1-38 months). No patient receiving postoperative
chemotherapy prior to chemoradiotherapy progressed
Table 1 Baseline patient characteristics
Patient Characteristic Number of Patients (%)
Male:Female Ratio 16:8
Average Age (range) years 62 (26-79)
Primary Site
Parotid 17 (71%)
Submandibular 3 (13%)
Minor - Base of Tongue 2 (8%)
Minor - Sphenoid Sinus 1 (4%)
Minor - Ethmoid Sinus 1 (4%)
Histology
Adenoid Cystic Carcinoma 5 (21%)
Mucoepidermoid Carcinoma 5 (21%)
Adenocarcinoma 3 (13%)
Squamous Cell Carcinoma 3 (13%)
Poorly Differentiated Carcinoma 3 (13%)
Carcinoma Ex-pleomorphic Adenoma 2 (8%)
Myoepithelial Carcinoma 1 (4%)
Salivary Duct Carcinoma 1 (4%)
Anaplastic Carcinoma 1 (4%)
T-Stage
1 1 (4%)
2 8 (33%)
3 6 (25%)
4a 7 (29%)
4b 2 (8%)
N-Stage
0 6 (25%)
1 3 (13%)
2a 0
2b 14 (58%)
2c 1 (4%)
30
Stage
II 1 (4%)
III 2 (8%)
IVA 19 (79%)
IVB 2 (8%)
Figure 1 Kaplan-Meier analysis of locoregional control.
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poorly differentiated histology developed lung
metastases.
Disease-Free and Overall Survival
The 3 and 5 year overall survival was 79% (95% CI: 54,
92) and 59% (95% CI: 31, 79), respectively, as shown in
Figure 2. Median and average survival were 42 months
and 52 months, respectively. The 3 and 5 year disease
free survival was 62% (95% CI: 38, 79) and 55% (95% CI:
31, 74), respectively. Table 2 summarizes disease-free
survival according to clinical and disease characteristics.
Univariate analysis of the clinical and pathological vari-
ables assessed did not reveal any differences in disease-
free survival. Three-year disease free survival in patients
with N2 disease was 49% compared to 86% in those
with N0 or N1 status (p = 0.14). There was also a trend
to improved disease free survival in patients receiving a
taxane-containing chemotherapy (80% vs. 45%, p =
0.17). Univariate analysis for overall survival demon-
strated that only nodal status was associated with statis-
tically significant improvements: N2 patients had a 5-
year survival rate of 42% vs. 100% for patients with N0
or N1 disease (p = 0.03). No patients with squamous
cell carcinoma experienced cancer recurrence: 2 patients
are alive at 39 and 63 months, while a third patient died
of natural causes at 98 months.
Toxicity
Acute treatment related toxicity included 46% grade 3
mucositis and 33% grade 3 hematologic toxicity. No
grade 4 toxicity was recorded during therapy. Six
patients required feeding tubes during treatment. Long-
term complications included persistent xerostomia in 5
patients, esophageal stricture requiring dilatation in 1
patient, and tempromandibular joint (TMJ) syndrome in
1 patient. Three patients (13%) had feeding tubes at last
follow-up or death. No patients required tracheostomy
during or after therapy.
Discussion
Concurrent chemotherapy and radiotherapy has been
shown to improve locoregional control and survival for
many tumor types [21]. For head and neck cancers, pri-
marily of squamous origin, concurrent chemoradiother-
apy has been shown to result in an absolute 10% 5 year
overall survival benefit [22]. Concurrent chemora-
diotherapy has been established as the standard of care
for many patients either definitively or adjuvantly with
locally advanced head and neck cancer.
Despite the proven benefit of concomitant chemora-
diotherapy for squamous and poorly differentiated head
and neck cancers, the impact for locoregionally
advanced and salivary gland malignancies is much less
clear. While several case reports of sequential or con-
current chemoradiotherapy for locoregionally advanced
salivary tumors exist, there is a paucity of data describ-
ing chemoradiotherapy in large series. Airoldi et al
described 6 patients with inoperable salivary malignancy
treated with radiotherapy to 66 Gy with concurrent
Figure 2 Kaplan-Meier analysis of overall survival.
Table 2 Disease-free survival by clinical and disease
characteristics
Factor Progressors/Total 3-y DFS (%) p-value
T-stage 0.99
T1-2 6/14 69
T3-4 5/10 56
Lymph Node Mets 0.14
N0/N1 2/8 86
N2 9/16 49
Tumor Grade 0.61
Low 3/5 53
High 8/19 64
Perineural Inv. 0.29
Absent 4/11 70
Present 7/13 55
Age 0.86
< 55 4/9 50
> 55 7/15 71
Gender 0.28
Male 6/16 72
Female 5/8 44
Dose > 63 Gy 0.81
Yes 6/15 63
No 5/9 50
TFHX 0.17
Yes 3/12 80
No 8/12 45
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Three patients had a complete response to therapy and
median survival was 18 months [23]. In the largest pre-
viously reported series we are aware of, seventeen
patients with Stage III or IV salivary malignancies were
treated with definitive chemoradiotherapy consisting of
daily radiotherapy to ~66 Gy and 2 monthly cycles of
cyclophosphamide, cisplatin, and pirarubicin [17]. Nine
patients had surgery for residual disease and 4 (24%)
patients had pathologic complete response with chemor-
adiotherapy alone. The current analysis describes the
largest series of patients treated with concurrent che-
moradiotherapy for advanced, high- risk salivary gland
malignancies. Our results compare favorably with the
smaller previously described series of chemoradiother-
apy, as the median survival for patients was 42 months
with one local failure noted.
The locoregional control rate in this report (96%)
compares favorably to large series of patients treated
with definitive surgery and radiotherapy or radiotherapy
alone. Published reports of surgery with or without
adjuvant radiotherapy for salivary cancer demonstrate
generally mediocre locoregional control rates, especially
for Stage IV disease. The University of Florida reported
locoregional control rates of 66% and 81%, for T4
tumors treated with surgery and surgery plus radiother-
apy, respectively. Chen et al has reported on 45 patients
with node-negative salivary malignancies treated with
definitive radiotherapy to ~66 Gy. The ultimate local
control rate was 57% and significantly worse for T3-4
tumors [24]. Laramore has summarized the published
literature of definitive photon/electron radiotherapy for
salivary gland malignancy and found a local control rate
of only 30%. This is in contrast to the rate found for
definitive fast neutron therapy, with a local control rate
of 67% [25]. In a matched-pair analysis of surgery versus
surgery plus radiotherapy, Armstrong et al reported that
local control for stage III and IV disease was only 51.3%
for combined treatment versus 16.8% for surgery alone
[1]. In a series of over 500 salivary malignancies, post-
operative radiotherapy improved local control over sur-
gery alone for T3-4 tumors (84% vs. 18%), in close (95%
vs. 55%) and incomplete resection (82% vs. 44%), and
presence of perineural invasion (88% vs. 60%) [9]. Data
from the Dutch Head and Neck Oncology Cooperative
Group demonstrated that postoperative radiotherapy
significantly improved regional control in the node posi-
tive neck, 86% vs. 62% for surgery alone. There were
zero regional failures in the 18 node positive patients
treated with chemoradiotherapy in this series. Current
NCCN recommendations for adjuvant radiotherapy
include intermediate and high grade, adenoid cystic his-
tology, close or positive margins, perineural invasion,
lymph node metastases and lymphovascular invasion.
Additionally, our results are promising when com-
pared to patients treated with neutron therapy. In the
University of Washington series of 279 patients, the 6-
year locoregional control was 59% and late Grade 3-4
toxicity was 10% [26]. In subset analysis, stage III-IV
(locoregional control 49%) and definitive radiotherapy
(locoregional control 40%) were associated with worse
outcomes. While the Medical Research Council (MRC)
trial demonstrated improved locoregional control for
patients with unresectable salivary gland malignancies
treated with fast neutron therapy, severe and life-threa-
tening complication rates were 69% and 15%, respec-
tively after neutron radiotherapy versus 33% and 8%
after photon radiotherapy [2]. The toxicity of neutron
therapy and limited accessibility, only 3 operating neu-
tron therapy centers in the United States, make photon
therapy a more reasonable and widely available treat-
ment. The acute and chronic toxicity of our regimen
was encouraging with limited acute mucositis and
hematologic toxicity. Chronic complications were also
limited given the advanced stage of the treated patients.
No fatalities in this series were thought to be treatment-
related.
The dominant pattern of progression seen in our ser-
ies was distant metastases, a relationship that has been
noted in previous studies of FHX-based chemora-
diotherapy [19]. This pattern of progression is consistent
with the natural history of salivary gland malignancy.
One hypothesis is that reducing distant progression
requires improved systemic therapy. There are a number
of Phase I and II trials that have investigated systemic
therapy with mixed results [26]. Molecular targeted
agents, including lapatinib and trastuzumab, have been
used as monotherapy in the metastatic setting with gen-
erally cytostatic results [27-29]. Future trials of chemor-
adiotherapy plus molecular targeted therapy may be
warranted for high-risk disease in the adjuvant setting
and is warranted in the setting of locally advanced
disease.
In patients with high- risk salivary gland malignancies
treated with adjuvant chemoradiotherapy, locoregional
control rates were favorable compared to other pub-
lished reports in the literature. In particular, locoregio-
nal control was high even in node positive patients
(93%) compared to 86% as reported in post-operative
patients from The Dutch Head and Neck Oncology
Cooperative Group [9]. Our data are limited by the ret-
rospective nature of the study, but the same is true of
almost all other published salivary gland malignancy
reports. Unlike squamous cell carcinomas of the head
and neck, where chemoradiotherapy has emerged as the
dominant treatment paradigm, little evidence supports
its use for salivary gland malignancy. However, our
locoregional control rates suggest that chemotherapy
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nous nature of salivary gland cancer limits the feasibility
of prospective clinical trials with adequate power. Cur-
rently, the RTOG has initiated a study to investigate the
role of adjuvant cisplatin based chemoradiotherapy for
high-risk salivary gland malignancies.
In conclusion surgical resection followed by adjuvant
chemoradiotherapy was associated with promising out-
comes in this series. Ongoing investigations will be
needed to verify the role of adjuvant chemoradiotherapy.
Integration of active systemic agents are needed to
reduce distant metastatic progression.
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